Latest news with #GSKPharma
&w=3840&q=100)
Business Standard
16-05-2025
- Business
- Business Standard
Fire disrupts production at GSK Pharma's contract manufacturing site
GSK Pharmaceuticals has reported a fire at one of its contract sites, causing temporary disruption; the company is assessing the impact and working to restore operations Anjali Singh Mumbai GlaxoSmithKline Pharmaceuticals (GSK Pharma) on Friday informed the stock exchanges that a fire had occurred at one of its contract manufacturing facilities, causing a temporary disruption in production at the site. While the exact location of the facility and the extent of the damage were not disclosed, the company said in a regulatory filing to the BSE and the National Stock Exchange (NSE) that it is currently assessing the impact of the incident and is working closely with the site to resume operations at the earliest. 'We are assessing the impact and working closely with the site to expedite resumption of operations,' the company said in the exchange filing. GSK Pharma is the Indian subsidiary of the UK-headquartered pharmaceutical giant GlaxoSmithKline, with a portfolio spanning prescription medicines and vaccines in India.
&w=3840&q=100)
Business Standard
14-05-2025
- Business
- Business Standard
Here's why GSK Pharma share price was buzzing in trade on Wednesday, May 14
GSK Pharma share price: GlaxoSmithKline Pharmaceuticals (GSK Pharma) shares were in demand on Wednesday, May 14, 2025, with the scrip rallying up to 8.46 per cent to hit an intraday high of Rs 3,026.20 per share. At 11:10 PM, however, the GSK Pharma shares were off highs, and were trading 4.18 per cent higher at Rs 906.85 per share. In comparison, BSE Sensex was trading 0.38 per cent higher at 81,460.24 level. What sparked the up move in GSK Pharma share price? The up move in the GSK Pharma share price came after the company posted a healthy March quarter of financial year 2025 (Q4FY25) results. For the quarter ended March 31, 2025 (Q4FY25), GSK Pharma reported a revenue of Rs 966 crore, a like-to-like growth of 6 per cent. The profit after tax (PAT) for the quarter stood at Rs 260 crore. Meanwhile, the company reported full year revenue of Rs 3,723 crore, a growth of 9 per cent from FY24. The PAT before exceptional items (bei) zoomed 32 per cent to Rs 915 crore, and Ebitda margins expanded 500 basis points (bps) to 31.4 per cent. Bhushan Akshikar, managing director, GlaxoSmithKline Pharmaceuticals, said, 'Our diversified portfolio of General Medicines, Specialty, and Vaccines has shown improved growth due to sustained innovation, enhanced Healthcare Professionals (HCP) engagement and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers. Our key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a significant role in driving growth throughout the year. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country.' 'We remain committed to delivering sustained above-market growth and strong shareholder returns. In FY2025-26, we will continue to focus on our innovative portfolio through the launch of our oncology assets,' Akshikar added. Furthermore, the company revealed that it is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer and Jemperli (Dostarlimab), an immunotherapy approved for the second-line treatment of endometrial cancer. GSK Pharma dividend, record date The Board has recommended a final dividend of Rs 42 per equity share on face value of Rs 10 each for the year ended March 31, 2025, subject to approval of members at 100th Annual General Meeting (AGM). The Company has fixed Friday, May 30, 2025, as the 'Record Date' for determining entitlement of members to final dividend for FY25. About GSK Pharma GlaxoSmithKline (GSK) Pharmaceuticals is a global healthcare company specialising in vaccines, specialty medicines, and general medicines. It operates under GSK plc, a British multinational pharmaceutical corporation headquartered in London. GSK India, a subsidiary of GSK plc, is a biopharmaceutical company engaged in the development and marketing of vaccines and medicines, with a strong focus on infectious diseases, HIV, oncology, and immunology.\
&w=3840&q=100)
Business Standard
14-05-2025
- Business
- Business Standard
Stock Market LIVE: Broader markets outperform Sensex, Nifty in volatile session; Metal index up 2%
Sensex Today | Stock Market LIVE Updates: Among sectors, the metal index was the top gainer, followed by Realty, Oil and IT indices, while financials, FMCG and Pharma were under pressure 1:54 PM Stock Market LIVE Updates: Here's why GSK Pharma share price was buzzing in trade on May 14 Stock Market LIVE Updates: Shares of GlaxoSmithKline Pharmaceuticals (GSK Pharma) saw strong demand on Wednesday, May 14, 2025, rallying by as much as 8.46 per cent to an intraday high of ₹3,026.20 per share. However, by around 11:10 AM, the stock had retreated from its peak, trading 4.18 per cent higher at ₹906.85 per share. This positive movement occurred while the BSE Sensex was also up, trading 0.38 per cent higher at 81,460.24. The reason for the upward movement in GSK Pharma's share price is currently being investigated. 1:33 PM Stock Market LIVE Updates: Accretion Pharmaceuticals IPO Day 1: Check subscription, GMP, key dates Stock Market LIVE Updates: The Initial Public Offering (IPO) of Accretion Pharmaceuticals opened for subscription in Delhi today, Wednesday, May 14, 2025, and has received a decent initial response. Within the first hour of opening, the SME public issue was subscribed approximately 25 per cent, according to NSE data (as of 11:15 AM IST). The retail investor portion was booked 43 per cent, while the Non-Institutional Investors' (NIIs) quota was subscribed 9 per cent. There were no bids from Qualified Institutional Buyers (QIBs) at that time. The company has allocated 50 per cent of the issue to QIBs, 35 per cent to retail investors, and 15 per cent to NIIs. READ MORE 1:12 PM Stock Market LIVE Updates: Garden Reach Shipbuilders share zooms 18% as Q4 profit more than doubles Stock Market LIVE Updates: Garden Reach Shipbuilders & Engineers shares were buzzing in trade on Wednesday, May 14, 2025, with the scrip skyrocketing 18.25 per cent to hit an intraday high of Rs 2,264.65 per share. However, at 12:00 noon, Garden Reach Shipbuilders shares were off day's high, and were trading 15.78 per cent higher at Rs 2,217.20 per share. In comparison, BSE Sensex was trading 0.20 per cent higher at 81,313.27 level. 12:55 PM Stock Market LIVE Updates: Defence stock surges 26% in 1 wk, zooms 100% from March low; hits new high Stock Market LIVE Updates: Shares of Bharat Dynamics Limited (BDL) reached a new all-time high of ₹1,821.95 on the BSE in Wednesday's intraday trade in Delhi, gaining 4 per cent on the back of a strong order book position. This surpasses its previous high of ₹1,794.70 from July 5, 2024. The state-owned aerospace & defence company's stock has now risen for five consecutive trading days, rallying 27 per cent in the past week, significantly outperforming the BSE Sensex's 1 per cent gain. BDL's market price has doubled since its March 2025 low of ₹908.90 on the BSE. READ MORE 12:42 PM Stock Market LIVE Updates: NSE sector heat map - Metal, Realty, Energy gain Stock Market LIVE Updates: Among sectors, the Nifty Metal was the top gainer, climbing 2.10 per cent, followed by Realty (up 1.33 per cent), Energy (up 1.06 per cent), among others. in contrast, the Nifty Bank was lower by 0.38 per cent, followed by Financial Services (down 0.32 per cent), and FMCG (down 0.21 per cent). 12:38 PM Stock Market LIVE Updates: NSE broader market heat map - Small, Midcaps gain Stock Market LIVE Updates: The broader market indices were higher, with the Nifty Midcap 100 index gaining 0.85 per cent, and the Nifty Smallcap 100 climbing 1.34 per cent. 12:34 PM Stock Market LIVE Updates: Nifty50 heat map - Tata Motors, Asian Paint, Cipla drag Stock Market LIVE Updates: On the Nifty50, 38 stocks were trading higher, while the rest declined. Gains were led by Tata Steel (up 4.10 per cent), followed by BEL, Hindalco Industries, Shriram Finance, and ONGC, while losses were capped by Tata Motors (down 1.75 per cent), followed by Asian Paint, Cipla, Power Grid and Kotak Mahindra Bank. 12:30 PM Stock Market LIVE Updates: BSE Sensex heat map - Tata Motors, Asian Paints, Kotak Mahindra Bank weigh Stock Market LIVE Updates: On the 30-stock BSE Sensex, nine stocks were trading lower, including Tata Motors (down 1.80 per cent), followed by Asian Paint, Kotak Mahindra Bank, Power Grid, and ICICI Bank, while gains were led by Tata Steel (up 4.01 per cent), followed by Mahindra Mahindra, Tech Mahindra, Eternal, and IndusInd Bank. 12:22 PM Stock Market LIVE Updates: MSCI rejig: Time to buy these 5 stocks for your portfolio? What charts say Stock Market LIVE Updates: The MSCI, in its semi-annual review, announced addition of Coromandel International and FSN E-Commerce Ventures (Nykaa) to its MSCI Global Standard Index, with effect from June 2025 onwards. Among other key additions, MSCI has included GMR Airports in its MSCI India Domestic Index. That apart, 12 stocks namely - Acme Solar Holdings, Authum Investment, Awl Agri Business, Dr Agarwal's Health Care, Godrej Agrovet, Hexaware Technologies, International Gemmological, Le Travenues Technology, Premier Energies, Sagility India, Sai Life Sciences and Sona Blw Precision - will be part of the MSCI India Domestic Smallcap Index.
Business Upturn
14-05-2025
- Business
- Business Upturn
GSK Pharma share price jumps 5% as Q4 EBITDA rises 29.5% YoY to Rs 333.2 crore
GSK Pharma's shares surged 5% following the release of its Q4 FY25 financial results. The company's consolidated revenue for the quarter increased by 4.8%, reaching Rs 974.4 crore compared to Rs 929.8 crore in the same period last year. The company's EBITDA saw a significant growth of 29.5%, rising to Rs 333.2 crore from Rs 257.3 crore in Q4 FY24. This resulted in a margin improvement to 34.2%, up from 27.7% in the previous year. GSK Pharma's net profit also experienced a strong jump, rising by 35% to Rs 262.9 crore from Rs 194.5 crore in Q4 FY24. The robust performance reflects a positive trend in the company's operational efficiency and profitability. The Board of Directors has proposed a final dividend of ₹42 per equity share on a face value of ₹10 each for the year ending March 31, 2025, subject to approval at the 100th Annual General Meeting. The record date for the dividend has been set for May 30, 2025. GSK Pharma shares opened at 2,914.10, with a high of 3,025.00 and a low matching the opening value at 2,914.10. The stock's 52-week high stands at 3,148.00, while the 52-week low is 1,921.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
&w=3840&q=100)
Business Standard
13-05-2025
- Business
- Business Standard
GSK Pharma Q4 profit rises 35% to ₹263 crore on strong brand growth
GlaxoSmithKline (GSK) Pharmaceuticals on Tuesday announced a 35 per cent year-on-year (YoY) increase in consolidated net profit for the March quarter (Q4FY25) to ₹262.87 crore, up from ₹194.48 crore in the same period last year. The company's revenue from operations rose 4.8 per cent YoY to ₹974.37 crore, from ₹929.80 crore in Q4FY24. The performance is attributed to strong growth across key product portfolios. Sequentially, the company's net profit declined 14.3 per cent, while revenue rose 2.6 per cent from ₹229.88 crore and ₹949.42 crore, respectively, reported in Q3FY25. GSK Pharma said that flagship brands within its general medicines portfolio — including Augmentin, Calpol, Ceftum and T-Bact — strengthened their market positions with share gains. Bhushan Ashikar, Managing Director, GSK Pharma, said the company's diversified portfolio of general medicines, specialty products and vaccines had shown improved growth due to sustained innovation, enhanced healthcare professional (HCP) engagement and rapid digital acceleration. 'This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers,' he added. Ashikar stated that the company will continue to focus on its innovative portfolio through the launch of oncology assets in the financial year (FY) 2025–26. 'The company is on track to launch Zejula (niraparib), a PARP inhibitor for ovarian cancer, and Jemperli (dostarlimab), an immunotherapy approved for the second-line treatment of endometrial cancer,' GSK Pharma said in a public statement. In the vaccines segment, the company maintained its leadership within the private market, with its paediatric vaccines portfolio — including Boostrix, Varilrix and Havrix — despite inclusion in the National Immunisation Programme (NIP) and rising competition. 'Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country,' the company said. On Tuesday, GSK Pharma's stock rose 2.49 per cent, ending the day's trade at ₹2,789 on the Bombay Stock Exchange (BSE).
